rss
Thorax 2007;62:276-277 doi:10.1136/thx.2004.035519
  • Case Report

Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody

  1. Cornelis K van der Ent1,
  2. Hans Hoekstra2,
  3. Ger T Rijkers3
  1. 1Department of Pediatric Respiratory Diseases, University Medical Center Utrecht, Utrecht, The Netherlands
  2. 2Department of Pediatrics, Hieronymus Bosch Hospital, Hertogenbosch, The Netherlands
  3. 3Department of Pediatric Immunology, University Medical Center Utrecht, Utrecht, The Netherlands
  1. Correspondence to:
    Dr C K van der Ent
    Department of Pediatric Respiratory Diseases, University Medical Center Utrecht, KH 01.419.0, PO Box 85090, 3508 AB Utrecht, The Netherlands; k.vanderent{at}wkz.azu.nl
  • Received 30 September 2004
  • Accepted 17 January 2005

Abstract

Allergic bronchopulmonary aspergillosis (ABPA) can cause severe worsening of the respiratory condition in patients with cystic fibrosis. Treatment can result in steroid dependency and serious adverse events. A dramatic and rapid improvement of respiratory symptoms and lung function after a single dose of anti-IgE antibody (omalizumab) in a 12-year-old girl with cystic fibrosis and ABPA is described. This is the first report of this experimental treatment. It suggests an important role for IgE in the pathogenesis of ABPA and offers new therapeutic possibilities.

Footnotes

  • Funding: None.

  • Competing interests: None.

Register for free content


Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of Thorax.
View free sample issue >>

Free archive
The full back archive is now available for Thorax. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006, back to volume 1 issue 1.
Register to access the free archive >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.